Synopsis
Decide when renal tissue can change diagnosis or treatment, prepare safely for biopsy and translate compartment-specific pathology into an integrated clinicopathological conclusion.
- Biopsy is justified when the likely information can alter treatment, prognosis, counselling or eligibility for a specialist therapy and the answer cannot be obtained safely by less invasive means.
- Common native-kidney indications include unexplained progressive impairment, nephritic or nephrotic presentations, significant proteinuria, suspected glomerular or interstitial disease and selected systemic disorders.
- The decision belongs to a renal specialist with the patient. Small kidneys, uncontrolled hypertension, bleeding disorders, a solitary kidney, obesity, frailty or inability to cooperate raise risk or reduce yield but require individual assessment rather than a memorised absolute list.
- Correct reversible bleeding risk before biopsy and create a documented, indication-specific plan for every anticoagulant and antiplatelet drug; interruption may itself cause stroke, valve thrombosis or recurrent venous thromboembolism.
- Ultrasound is used to choose a safe route, assess kidney size and guide the needle. Modern native biopsy is usually percutaneous and image-guided, with alternative approaches reserved for specialist circumstances.
- The cortex contains glomeruli. Adequacy is not merely core length: tissue must be divided promptly and appropriately for light microscopy, immunofluorescence or immunohistology and, when needed, electron microscopy.
- Read a report by compartments—glomeruli, tubules, interstitium and vessels—then separate active potentially reversible lesions from chronic scarring such as global sclerosis, tubular atrophy and interstitial fibrosis.
- Immunofluorescence describes immune deposits and their location; electron microscopy resolves basement membranes, podocyte foot processes and small deposits. Neither should be interpreted without light microscopy and clinical serology.
- A biopsy diagnosis is a sample from one time and place. Focal disease can be missed, treatment can modify appearances and chronic damage may limit the value of aggressive immunosuppression despite a named diagnosis.
- Bleeding is the principal procedural complication. UK Kidney Association NEPHwork audit data recorded complications in 5.8% and major complications in 1.9% of 1,713 native biopsies, reinforcing the need for consent and post-procedure surveillance.
Key red flags
A rapid creatinine rise with haematuria, proteinuria, red-cell casts, hypertension and systemic vasculitic or pulmonary features suggests active crescentic disease. Urgent serology and nephrology discussion run in parallel with expedited biopsy planning.
Heavy protein loss, hypoalbuminaemia and oedema can arise from primary glomerular disease, diabetes, amyloid, lupus, medicines or malignancy. Histology is often important in adults when a non-invasive diagnosis is not secure.
Persistent renal decline after perfusion and obstruction are addressed, especially with pyuria, eosinophilia, haematuria or drug exposure, raises tubular, interstitial or glomerular disease for which tissue may change management.
Lupus features, vasculitis, chronic infection, paraprotein, amyloid phenotype or complement disturbance may require biopsy to classify renal involvement and assess irreversible damage before hazardous treatment.
New severe flank or abdominal pain, tachycardia, hypotension, visible blood, reduced urine from clots, presyncope or haemoglobin fall can indicate perinephric or urinary bleeding and needs prompt imaging and senior escalation.
Investigation priorities
Identify anaemia, thrombocytopenia or coagulation abnormality and prepare for haemorrhage according to procedural policy.
Management branches
A renal syndrome remains unexplained after initial blood, urine and imaging assessment.
- Construct a narrow differential from acuity, eGFR trajectory, protein loss, sediment, serology, medicines and systemic features, and state the unresolved management decision.
- Discuss with nephrology whether tissue is likely to distinguish actionable diagnoses or quantify activity and chronicity better than non-invasive tests.
- Explain alternatives, the possibility of a non-diagnostic sample, bleeding risk and how each plausible result would change therapy before obtaining consent.